AbbVie Biotechnology Ltd. 13D and 13G filings for Carisma Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-25 4:15 pm Sale |
2025-03-31 | 13G | Carisma Therapeutics, Inc. CARM |
AbbVie Biotechnology Ltd. | 1,855,871 4.400% |
-893,984 (-32.51%) |
Filing |
| 2024-03-13 4:30 pm Purchase |
2023-12-31 | 13G | Carisma Therapeutics, Inc. CARM |
AbbVie Biotechnology Ltd. | 2,749,855 6.800% |
2,749,855 (New Position) |
Filing |